AN0025 — Topline data
H1 2027
The futility analysis of this Phase II study was successfully passed in March 2026, and the topline results are expected in the first half of 2027.Source filing
ANL biotech catalysts & pipeline
ADLAI NORTYE LTD · Data as of 2026-09-08
Upcoming catalysts
AN9025 — Initial data
H1 2027
The Company remains on track to share initial Phase Ia dose escalation data in the first half of 2027 from the QD arm, with a potential early look at the QW arm.Source filing
AN4035 — Initial data
H2 2027
The Company is on track to dose the first patient with AN4035 in the second half of 2026, and initial clinical data is expected to be available in the second half of 2027.Source filing
AN4005 — Conference presentation
Nov 4–Nov 8
A clinical update from the ongoing expansion cohorts is expected to be presented at the 2026 Society for Immunotherapy of Cancer (SITC) meeting.Source filing